Cross-Sector entity
Across a 139-day span, the pace is roughly 0.6 stories per week. The busiest single day carried 5. Brookings Institution is most often covered alongside House Select Committee on China, which appears in 5 of these 11 stories. regulation accounts for 6 of the 11 tracked stories, while 4 other categories carry the remainder.
11 verified stories tracked
Last mentioned: Jul 9, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 64 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Across a 139-day span, the pace is roughly 0.6 stories per week. The busiest single day carried 5. Brookings Institution is most often covered alongside House Select Committee on China, which appears in 5 of these 11 stories. regulation accounts for 6 of the 11 tracked stories, while 4 other categories carry the remainder. 64% of these stories carry negative sentiment. The tracked stories average 2.8 original sources each. This profile follows 11 Cross-Sector stories mentioning Brookings Institution across the period from February 21, 2026 to July 9, 2026.
Computed from the 11 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Brookings Institution. Shared-story counts are live from our verified record — not editorial picks.
Former Fed Chair Ben Bernanke's appointment to Anthropic's independent trust adds deep economic firepower as the $965 billion AI firm eyes a public debut, focusing his Nobel-winning expertise on AI's macro impacts.
Source: CNBC · Seeking Alpha
The immediate loss of 20 million barrels per day of oil is sending financial markets into uncharted territory. Inflationary expectations have unanchored, the IMF has slashed global growth forecasts, and central banks face an impossible trilemma between growth, inflation, and financial stability.
The Iran War’s 20-million-barrel daily oil disruption has jolted energy policies worldwide. The crisis is proving a double-edged sword for the climate: it accelerates renewable energy investments as an energy security imperative, yet also risks a coal resurgence and stretching green funding thin.
Source: Dr Mohamed Chtatou · Dr Mohamed Chtatou
The U.S. government's AI contracts have more than tripled to over 1,700 in four years, with $90B in spending, yet fears about AI's societal impact mirror historical panics that led to policy mistakes. For AI developers and researchers, this tension could define the regulatory landscape.
Source: Andrew Caballero-Reynolds (us) · Andrew Caballero-Reynolds (us)
The House Select Committee on China has warned that Beijing is executing a strategic 'playbook' to dominate the global pharmaceutical market, mirroring its previous successes in rare earths and electric vehicles. With Chinese medical revenue projected to reach $2.1 trillion by 2030, US officials are weighing the national security risks of a supply chain heavily dependent on Chinese-made active pharmaceutical ingredients.
The House Select Committee on China has warned that Beijing is executing a long-term strategy to dominate the global pharmaceutical market, mirroring its tactics in the rare earth and EV sectors. With China's drug and medical device revenue projected to reach $2.1 trillion by 2030, US officials are calling for urgent action to reduce reliance on Chinese-made active pharmaceutical ingredients.
A high-profile House Select Committee hearing has highlighted the United States' critical dependence on Chinese active pharmaceutical ingredients (APIs). Lawmakers warn that Beijing is applying its successful industrial playbook from rare earths and EVs to corner the global medicine market, with Chinese pharma revenue projected to hit $2.1 trillion by 2030.
US lawmakers are raising alarms over the pharmaceutical industry's reliance on Chinese ingredients, warning that Beijing is applying its 'rare earths playbook' to dominate global medicine. A House Select Committee hearing highlighted concerns that China's control over active pharmaceutical ingredients and the biotech pipeline poses a strategic threat to American healthcare security.
The House Select Committee on China has raised alarms over the United States' increasing reliance on Chinese-made active pharmaceutical ingredients and biotech innovation. Lawmakers argue that Beijing is applying a proven industrial playbook to dominate the global medicine supply chain, posing significant national security and regulatory challenges.
Source: Lucy Quaggin (cn) · Lucy Quaggin (hk)
Tencent CEO Pony Ma has admitted the tech giant was "slow" to react to the generative AI revolution, contrasting with the aggressive multi-billion dollar investment strategies of rivals Alibaba and ByteDance. This divergence marks a critical juncture for Chinese Big Tech as they navigate varying capital expenditure paths in the global race for AI dominance.
Tencent CEO Pony Ma has admitted the social media giant was "slow" to react to the AI revolution, signaling a conservative approach compared to rivals. While Alibaba and ByteDance commit hundreds of billions to aggressive AI expansion, Tencent’s "measured pace" highlights a growing strategic divide among China's technology leaders.
Source: Iris Deng (hk) · Iris Deng (cn)
